Solubility-Permeability-Matrix Interplay in Percutaneous Absorption Exemplified by Theophylline.
AAPS PharmSciTech 2026 Mar 06; 27(3).

Abstract

The stratum corneum represents the main barrier to transdermal drug delivery, particularly for hydrophilic and ionized compounds such as aminophylline. In this study, the solubility-permeability-matrix interplay was investigated using aminophylline and theophylline as model drugs in various matrix-type transdermal patches based on either hydroxypropyl methylcellulose (HPMC) or silicone-based Bio-PSA (Biomedical Pressure-Sensitive Adhesive). Franz diffusion cells with porcine ear skin were used to evaluate in vitro skin permeation, and complementary release studies were conducted using dialysis membranes. Aminophylline exhibited significantly higher transdermal flux than theophylline in both matrix systems, despite its increased hydrophilicity and ionization. This effect is attributed to its capacity to maintain high thermodynamic activity when formulated as a suspension, thereby intensifying chemical potential gradients and supporting aqueous pathway permeation. Penetration enhancers showed distinct mechanisms of action. Geraniol, a lipophilic terpene alcohol, significantly increased skin permeation by disrupting stratum corneum lipid lamellae and facilitating transient hydrophilic channels. In contrast, Transcutol P acted primarily by increasing drug solubility within the matrix and forming a reservoir in the stratum corneum. However, its enhancing effect remained modest due to limited interaction with the barrier and slow release from the silicone matrix. These findings highlight the critical role of drug solubility and enhancer molecular properties in the transdermal delivery of hydrophilic drugs. In addition, matrix parameters like thickness, hydration and release properties need to be properly engineered for making optimal use of the involved solubility-permeability interplay.

Authors+Show Affiliations

Engel S0009-0005-3817-6225Department of Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg University Mainz, 55128, Mainz, Germany.
Al-Gousous J0000-0001-7994-4175Department of Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg University Mainz, 55128, Mainz, Germany.
Grünewald C0009-0008-4278-6896Microbiology and Biotechnology at the Institute of Molecular Physiology, Johannes Gutenberg University Mainz, 55128, Mainz, Germany.
Jacob C0000-0001-9567-3950Institute of Developmental Biology and Neurobiology, Faculty of Biology, Johannes Gutenberg University Mainz, 55128, Mainz, Germany.
Langguth P0000-0003-3758-7581Department of Biopharmaceutics and Pharmaceutical Technology, Johannes Gutenberg University Mainz, 55128, Mainz, Germany. langguth@uni-mainz.de.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

41792385